| Autor: |
Drost, FJH, Nieboer, D, Morgan, TM, Carroll, PR, Roobol, MJ, Trock, B, Ehdaie, B, Carroll, P, Filson, C, Kim, J, Logothetis, C, Morgan, T, Klotz, L, Pickles, T, Hyndman, E, Moore, CM, Gnanapragasam, V, Van Hemelrijck, M, Dasgupta, P, Bangma, C, Roobol, M, Villers, A, Rannikko, A, Valdagni, R, Perry, A, Hugosson, J, Rubio-Briones, J, Bjartell, A, Hefermehl, L, Shiong, LL, Frydenberg, M, Kakehi, Y, Chung, BH, van der Kwast, T, van der Linden, W, Hulsen, T, de Jonge, C, Kattan, M, Xinge, J, Muir, K, Lophatananon, A, Fahey, M, Steyerberg, E, Zhang, L, Beckmann, K, Denton, B, Hayen, A, Boutros, P, Guo, W, Benfante, N, Cowan, J, Patil, D, Tolosa, E, Kim, TK, Mamedov, A, Lapointe, V, Crump, T, Kimberly-Duffell, J, Santaolalla, A, Olivier, J, Rancati, T, Ahlgren, H, Mascarós, J, Löfgren, A, Lin, CH, Hirama, H, Lee, KS, Jenster, G, Auvinen, A, Haider, M, van Bochove, K, Carter, B, Gledhill, S, Buzza, M, Bruinsma, S, Helleman, J |
| Rok vydání: |
2019 |
| Předmět: |
|
| Popis: |
© 2019 European Association of Urology Two active surveillance risk calculators to predict disease reclassification on prostate biopsy are externally validated by the Movember Foundation's Global Action Plan (GAP3) consortium. They proved to be clinically useful and could reduce unnecessary biopsies, but need recalibration to local settings. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
